Pathophysiology of circulating xanthine oxidoreductase: New emerging roles for a multi-tasking enzyme

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 9, 2014, Pages 1502-1517

  Battelli, Maria Giulia ^a   Bolognesi, Andrea ^a   Polito, Letizia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cardiovascular diseases; Endothelium functions; Metabolic syndrome; Oxidative stress; Uric acid; Xanthine oxidoreductase

Indexed keywords

OXIDOREDUCTASE; XANTHINE OXIDASE;

ANTINOCICEPTION; APOPTOSIS; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; BRAIN ISCHEMIA; CHEMICAL STRUCTURE; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LOCALIZATION; ENZYME REGULATION; HEART FAILURE; HEART INFARCTION; HEPATITIS; HUMAN; HYPERTENSION; LIVER INJURY; LIVER ISCHEMIA; LIVER TRANSPLANTATION; NONHUMAN; ORGAN DISTRIBUTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SPECIES DISTRIBUTION; TISSUE DISTRIBUTION; TISSUE INJURY;

CARDIOVASCULAR DISEASES; ENDOTHELIUM FUNCTIONS; METABOLIC SYNDROME; OXIDATIVE STRESS; URIC ACID; XANTHINE OXIDOREDUCTASE;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; METABOLIC SYNDROME X; XANTHINE DEHYDROGENASE;

EID: 84903624691     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.05.022     Document Type: Review

References (302)

1. Morgan E.J., Stewart C.P., Hopkins F.G. On the anaerobic and aerobic oxidation of xanthin and hypoxanthin by tissues and by milk. Proc. R. Soc. Lond. B 1922, 94:109-131.
2. De Renzo E.C. Chemistry and biochemistry of xanthine oxidase. Adv. Enzymol. Relat. Subj. Biochem. 1956, 17:293-328.
3. Kooij A. A re-evaluation of the tissue distribution and physiology of xanthine oxidoreductase. Histochem. J. 1994, 26:889-915.
4. Massey V., Harris C.M. Milk xanthine oxidoreductase: the first one hundred years. Biochem. Soc. Trans. 1997, 25:750-755.
5. Mateos F.A., Puig J.G., Jiménez M.L., Fox I.H. Hereditary xanthinuria. Evidence for enhanced hypoxanthine salvage. J. Clin. Invest. 1987, 79:847-852.
6. Schmidt A.P., Böhmer A.E., Antunes C., Schallenberger C., Porciúncula L.O., Elisabetsky E., Lara D.R., Souza D.O. Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors. Br. J. Pharmacol. 2009, 156:163-172.
7. Krenitsky T.A., Neil S.M., Elion G.B., Hitchings G.H. A comparison of the specificities of xanthine oxidase and aldehyde oxidase. Arch. Biochem. Biophys. 1972, 150:585-599.
8. Beedham C. Xanthine oxidoreductase and aldehyde oxidase. Comprehensive toxicology 2010, 4:185-205. Elsevier, Oxford. C.A. McQueen (Ed.).
9. Taibi G., Di Gaudio F., Nicotra C.M. Xanthine dehydrogenase processes retinol to retinoic acid in human mammary epithelial cells. J. Enzyme Inhib. Med. Chem. 2008, 23:317-327.
10. Bergmann F., Levene L., Tamir I., Rahat M. Oxidation of methyl derivatives of pteridin-4-one, lumazine and related pteridines by bovine milk xanthine oxidase. Biochim. Biophys. Acta 1977, 480:21-38.
11. Pritsos C.A. Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem. Biol. Interact. 2000, 129:195-208.
12. Bray R.C. Molybdenum iron-sulfur flavin hydroxylases and related enzymes. The enzymes 1975, 12:299-419. Academic Press, New York. P.D. Boyer (Ed.).
13. McCord J.M., Fridovich I. The reduction of cytochrome c by milk xanthine oxidase. J. Biol. Chem. 1968, 243:5753-5760.
14. Kuppusamy P., Zweier J.L. Characterization of free radical generation by xanthine oxidase. Evidence for hydroxyl radical generation. J. Biol. Chem. 1989, 264:9880-9884.
15. Hsu D.Z., Chen K.T., Chien S.P., Li Y.H., Huang B.M., Chuang Y.C., Liu M.Y. Sesame oil attenuates acute iron-induced lipid peroxidation-associated hepatic damage in mice. Shock 2006, 26:625-630.
16. Parks D.A., Bulkley G.B., Granger D.N. Role of oxygen free radicals in shock, ischemia, and organ preservation. Surgery 1983, 94:428-432.
17. Topham R.W., Walker M.C., Calisch M.P. Liver xanthine dehydrogenase and iron mobilization. Biochem. Biophys. Res. Commun. 1982, 109:1240-1246.
18. Topham R.W., Walker M.C., Calisch M.P., Williams R.W. Evidence for the participation of intestinal xanthine oxidase in the mucosal processing of iron. Biochemistry 1982, 21:4529-4535.
19. Stirpe F., Higgins T., Tazzari P.L., Rozengurt E. Stimulation by xanthine oxidase of 3T3 Swiss fibroblasts and human lymphocytes. Exp. Cell Res. 1991, 192:635-638.
20. Rao G.N., Berk B.C. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ. Res. 1992, 70:593-599.
21. Galli A., Svegliati-Baroni G., Ceni E., Milani S., Ridolfi F., Salzano R., Tarocchi M., Grappone C., Pellegrini G., Benedetti A., Surrenti C., Casini A. Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology 2005, 41:1074-1084.
22. Tubaro E., Lotti B., Santiangeli C., Cavallo G. Xanthine oxidase: an enzyme playing a role in the killing mechanism of polymorphonuclear leucocytes. Biochem. Pharmacol. 1980, 29:3018-3020.
23. Petrone W.F., English D.K., Wong K., McCord J.M. Free radicals and inflammation: superoxide-dependent activation of a neutrophil chemotactic factor in plasma. Proc. Natl. Acad. Sci. U. S. A. 1980, 77:1159-1163.
24. Ehrlich W., Huser H., Kroger H. Induction and activation of procollagenase in rabbit synovial fibroblasts after treatment with active oxygen released by xanthine/xanthine oxidase. Rheumatol. Int. 1995, 15:131-136.
25. Suzuki M., Grisham M.B., Granger D.N. Leukocyte-endothelial cell adhesive interactions-role of xanthine oxidase-derived oxidants. J. Leukoc. Biol. 1991, 50:488-494.
26. Shenkar R., Abraham E. Plasma from hemorrhaged mice activates CREB and increases cytokine expression in lung mononuclear cells through a xanthine oxidase-dependent mechanism. Am. J. Respir. Cell Mol. Biol. 1996, 14:198-206.
27. Müller M.J., Vollmar B., Friedl H.P., Menger M.D. Xanthine oxidase and superoxide radicals in portal triad crossclamping-induced microvascular reperfusion injury in the liver. Free Radic. Biol. Med. 1996, 21:189-197.
28. Segal B.H., Sakamoto N., Patel M., Maemura K., Klein A.S., Holland S.M., Bulkley G.B. Xanthine oxidase contributes to host defense against Burkholderia cepacia in the p47phox-/-mouse model of chronic granulomatous disease. Infect. Immun. 2000, 68:2374-2378.
29. Sanders S.A., Eisenthal R., Harrison R. NADH oxidase activity of human xanthine oxidoreductase-generation of superoxide anion. Eur. J. Biochem. 1997, 245:541-548.
30. Zhang Z., Blake D.R., Stevens C.R., Kanczler J.M., Winyard P.G., Symons M.C., Benboubetra M., Harrison R. A reappraisal of xanthine dehydrogenase and oxidase in hypoxic reperfusion injury: the role of NADH as an electron donor. Free Radic. Res. 1998, 28:151-164.
31. Maia L., Duarte R.O., Ponces-Freire A., Moura J.J., Mira L. NADH oxidase activity of rat and human liver xanthine oxidoreductase: potential role in superoxide production. J. Biol. Inorg. Chem. 2007, 12:777-787.
32. Godber B.L.J., Doel J.J., Durgan J., Eisenthal R., Harrison R. A new route to peroxynitrite: a role for xanthine oxidoreductase. FEBS Lett. 2000, 475:93-96.
33. Martin H.M., Hancock J.T., Salisbury V., Harrison R. Role of xanthine oxidoreductase as an antimicrobial agent. Infect. Immun. 2004, 72:4933-4939.
34. Harrison R. Structure and function of xanthine oxidoreductase: where are we now?. Free Radic. Biol. Med. 2002, 33:774-797.
35. Glantzounis G.K., Tsimoyiannis E.C., Kappas A.M., Galaris D.A. Uric acid and oxidative stress. Curr. Pharm. Des. 2005, 11:4145-4151.
36. Ames B.N., Cathcart R., Schwiers E., Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:6858-6862.
37. Berry C.E., Hare J.M. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J. Physiol. 2004, 555:589-606.
38. Nguyen J. Plant xanthine dehydrogenase: its distribution, properties and function. Physiol. Vég. 1986, 24:263-281.
39. Parks D.A., Granger D.N. Xanthine oxidase: biochemistry, distribution and physiology. Acta Physiol. Scand. Suppl. 1986, 548:87-99.
40. Della Corte E., Stirpe F. The regulation of rat liver xanthine oxidase: activation by proteolytic enzymes. FEBS Lett. 1968, 2:83-84.
41. Battelli M.G., Della Corte E., Stirpe F. Xanthine oxidase type D (dehydrogenase) in the intestine and other organs of the rat. Biochem. J. 1972, 126:747-749.
42. Hille R., Nishino T. Xanthine oxidase and xanthine dehydrogenase. FASEB J. 1995, 9:995-1003.
43. Chung H.Y., Baek B.S., Song S.H., Kim M.S., Huh J.I., Shim K.H., Kim K.W., Lee K.H. Xanthine dehydrogenase/xanthine oxidase and oxidative stress. Age (Omaha) 1997, 20:127-140.
44. Kurosaki M., Li Calzi M., Scanziani E., Garattini E., Terao M. Tissue and cell-specific expression of mouse xanthine oxidoreductase gene in vivo: regulation by bacterial lipopolysaccharide. Biochem. J. 1995, 306:225-234.
45. Saksela M., Lapatto R., Raivio K.O. Xanthine oxidoreductase gene expression and enzyme activity in developing human tissues. Biol. Neonate 1998, 74:274-280.
46. Al-Khalidi U.A.S., Chaglassian T.H. The species distribution of xanthine oxidase. Biochem. J. 1965, 97:318-320.
47. Wang J., Van Praagh A., Hamilton E., Wang Q., Zou B., Muranjan M., Murphy N.B., Black S.J. Serum xanthine oxidase: origin, regulation, and contribution to control of trypanosome parasitemia. Antioxid. Redox Signal. 2002, 4:161-178.
48. Kooij A., Schijns M., Frederiks W.M., Van Noorden C.J.F., James J. Distribution of xanthine oxidoreductase activity in human tissues - a histochemical and biochemical study. Virchows Arch. B Cell Pathol. 1992, 63:17-23.
49. Angermüller S., Islinger M., Völkl A. Peroxisomes and reactive oxygen species, a lasting challenge. Histochem. Cell Biol. 2009, 131:459-463.
50. Riario-Sforza G., Carcassi A., Bayeli P.F., Marcolongo R., Marinello E., Montagnani M. Xanthine oxidase activity in the jejunal mucosa of patients with gout. Boll. Soc. Ital. Biol. Sper. 1969, 45:785-786.
51. Auscher C., Amory N., van der Kemp P., Delbarre F. Xanthine oxidase activity in human intestines. Histochemical and radiochemical study. Adv. Exp. Med. Biol. 1979, 122B:197-201.
52. Della Corte E., Gozzetti G., Novello F., Stirpe F. Properties of the xanthine oxidase from human liver. Biochim. Biophys. Acta 1969, 191:164-166.
53. Guerciolini R., Szumlanski C., Weinshilboum R.M. Human liver xanthine oxidase: nature and extent of individual variation. Clin. Pharmacol. Ther. 1991, 50:663-672.
54. Stirpe F., Ravaioli M., Battelli M.G., Musiani S., Grazi G.L. Xanthine oxidoreductase activity in human liver disease. Am. J. Gastroenterol. 2002, 97:2079-2085.
55. Watts R.W., Watts J.E., Seegmiller J.E. Xanthine oxidase activity in human tissues and its inhibition by allopurinol (4-hydroxypyrazolo[3,4-d] pyrimidine). J. Lab. Clin. Med. 1965, 66:688-697.
56. Sarnesto A., Linder N., Raivio K.O. Organ distribution and molecular forms of human xanthine dehydrogenase/xanthine oxidase protein. Lab. Invest. 1996, 74:48-56.
57. Rodkey F.L., Ball E.G. A rapid test for distinguishing human from cow's milk based upon a difference in their xanthine oxidase content. J. Lab. Clin. Med. 1946, 31:354-356.
58. Abadeh S., Killacky J., Benboubetra M., Harrison R. Purification and partial characterization of xanthine oxidase from human milk. Biochim. Biophys. Acta 1992, 1117:25-32.
59. Al-Khalidi U.A.S., Nasrallah S., Khachadurian A.K., Shammaa M.H. A sensitive method for the determination of xanthine oxidase activity. Clin. Chim. Acta 1965, 11:72-77.
60. Battelli M.G., Buonamici L., Abbondanza A., Virgili M., Contestabile A., Stirpe F. Excitotoxic increase of xanthine dehydrogenase and xanthine oxidase in the rat olfactory cortex. Dev. Brain Res. 1995, 86:340-344.
61. McHale A., Grimes H., Coughlan M.P. Human serum xanthine oxidase: fluorometric assay applicable to the investigation of liver disorders. Int. J. Biochem. 1979, 10:317-319.
62. Yamamoto T., Moriwaki Y., Takahashi S., Tsutsumi Z., Yamakita J., Nasako Y., Hiroishi K., Higashino K. Determination of human plasma xanthine oxidase activity by high-performance liquid chromatography. J. Chromatogr. B Biomed. Appl. 1996, 681:395-400.
63. Liu X., Lin W.M., Yan X.H., Chen X.H., Hoidal J.R., Xu P. Improved method for measurement of human plasma xanthine oxidoreductase activity. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2003, 785:101-114.
64. Stevens C.R., Benboubetra M., Harrison R., Sahinoglu T., Smith E.C., Blake D.R. Localisation of xanthine oxidase to synovial endothelium. Ann. Rheum. Dis. 1991, 50:760-762.
65. Price L.J., Harrison R. Sensitive enzyme linked immunosorbent assay (ELISA) for xanthine oxidase. Biochem. Soc. Trans. 1993, 21:102S.
66. Battelli M.G., Abbondanza A., Musiani S., Buonamici L., Strocchi P., Tazzari P.L., Gramantieri L., Stirpe F. Determination of xanthine oxidase in human serum by a competitive enzyme-linked immunosorbent assay (ELISA). Clin. Chim. Acta 1999, 281:147-158.
67. Nishino T., Okamoto K., Eger B.T., Pai E.F., Nishino T. Mammalian xanthine oxidoreductase - mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J. 2008, 275:3278-3289.
68. Ichida K., Amaya Y., Noda K., Minoshima S., Hosoya T., Sakai O., Shimizu N., Nishino T. Cloning of the cDNA encoding human xanthine dehydrogenase (oxidase): structural analysis of the protein and chromosomal location of the gene. Gene 1993, 133:279-284.
69. Wright R.M., Vaitaitis G.M., Wilson C.M., Repine T.B., Terada L.S., Repine J.E. cDNA cloning, characterization, and tissue-specific expression of human xanthine dehydrogenase/xanthine oxidase. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:10690-10694.
70. Saksela M., Raivio K.O. Cloning and expression in vitro of human xanthine dehydrogenase/oxidase. Biochem. J. 1996, 315:235-239.
71. Hewinson J., Stevens C.R., Millar T.M. Vascular physiology and pathology of circulating xanthine oxidoreductase: from nucleotide sequence to functional enzyme. Redox Rep. 2004, 9:71-79.
72. Xu P., LaVallee P., Hoidal J.R. Repressed expression of the human xanthine oxidoreductase gene. E-box and TATA-like elements restrict ground state transcriptional activity. J. Biol. Chem. 2000, 275:5918-5926.
73. Wallwork C.J., Parks D.A., Schmid-Schönbein G.W. Xanthine oxidase activity in the dexamethasone-induced hypertensive rat. Microvasc. Res. 2003, 66:30-37.
74. Reiners J.J., Pence B.C., Barcus M.C., Cantu A.R. 12-O-tetradecanoylphorbol-13-acetate-dependent induction of xanthine dehydrogenase and conversion to xanthine oxidase in murine epidermis. Cancer Res. 1987, 47:1775-1779.
75. Feigelson M., Feigelson P., Gross P.R. Xanthine oxidase activity in regenerating liver. J. Gen. Physiol. 1957, 41:233-242.
76. Pence B.C., Reiners J.J. Murine epidermal xanthine oxidase activity: correlation with degree of hyperplasia induced by tumor promoters. Cancer Res. 1987, 47:6388-6392.
77. Hoidal J.R., Xu P., Huecksteadt T., Sanders K.A., Pfeffer K., Sturrock A.B. Lung injury and oxidoreductases. Environ. Health Perspect. 1998, 106(Suppl. 5):1235-1239.
78. Roberts L.E., Fini M.A., Derkash N., Wright R.M. PD98059 enhanced insulin, cytokine, and growth factor activation of xanthine oxidoreductase in epithelial cells involves STAT3 and the glucocorticoid receptor. J. Cell. Biochem. 2007, 101:1567-1587.
79. Kayyali U.S., Budhiraja R., Pennella C.M., Cooray S., Lanzillo J.J., Chalkley R., Hassoun P.M. Upregulation of xanthine oxidase by tobacco smoke condensate in pulmonary endothelial cells. Toxicol. Appl. Pharmacol. 2003, 188:59-68.
80. Furth-Walker D., Amy N.K. Regulation of xanthine oxidase activity and immunologically detectable protein in rats in response to dietary protein and iron. J. Nutr. 1987, 117:1697-1703.
81. Schröder K., Vecchione C., Jung O., Schreiber J.G., Shiri-Sverdlov R., van Gorp P.J., Busse R., Brandes R.P. Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed a Western-type diet. Free Radic. Biol. Med. 2006, 41:1353-1360.
82. Zhang Z.W., Wang Q.H., Zhang J.L., Li S., Wang X.L., Xu S.W. Effects of oxidative stress on immunosuppression induced by selenium deficiency in chickens. Biol. Trace Elem. Res. 2012, 149:352-361.
83. Linder N., Bützow R., Lassus H., Lundin M., Lundin J. Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma. Gynecol. Oncol. 2012, 124:311-318.
84. McManaman J.L., Palmer C.A., Wright R.M., Neville M.C. Functional regulation of xanthine oxidoreductase expression and localization in the mouse mammary gland: evidence of a role in lipid secretion. J. Physiol. 2002, 545:567-579.
85. Kurosaki M., Zanotta S., Li Calzi M., Garattini E., Terao M. Expression of xanthine oxidoreductase in mouse mammary epithelium during pregnancy and lactation: regulation of gene expression by glucocorticoids and prolactin. Biochem. J. 1996, 319:801-810.
86. Page S., Powell D., Benboubetra M., Stevens C.R., Blake D.R., Selase F., Wolstenholme A.J., Harrison R. Xanthine oxidoreductase in human mammary epithelial cells: activation in response to inflammatory cytokines. Biochim. Biophys. Acta 1998, 1381:191-202.
87. Vorbach C., Scriven A., Capecchi M.R. The housekeeping gene xanthine oxidoreductase is necessary for milk fat droplet enveloping and secretion: gene sharing in the lactating mammary gland. Genes Dev. 2002, 16:3223-3235.
88. McManaman J.L., Palmer C.A., Anderson S., Schwertfeger K., Neville M.C. Regulation of milk lipid formation and secretion in the mouse mammary gland. Adv. Exp. Med. Biol. 2004, 554:263-279.
89. Aoki N. Regulation and functional relevance of milk fat globules and their components in the mammary gland. Biosci. Biotechnol. Biochem. 2006, 70:2019-2027.
90. Ghezzi P., Bianchi M., Mantovani A., Spreafico F., Salmona M. Enhanced xanthine oxidase activity in mice treated with interferon and interferon inducers. Biochem. Biophys. Res. Commun. 1984, 119:144-149.
91. Deloria L., Abbott V., Gooderham N., Mannering G.J. Induction of xanthine oxidase and depression of cytochrome P-450 by interferon inducers: genetic difference in the responses of mice. Biochem. Biophys. Res. Commun. 1985, 131:109-114.
92. Terao M., Cazzaniga G., Ghezzi P., Bianchi M., Falciani F., Perani P., Garattini E. Molecular cloning of a cDNA coding for mouse liver xanthine dehydrogenase. Regulation of its transcript by interferons in vivo. Biochem. J. 1992, 283:863-870.
93. Dupont G.P., Huecksteadt T.P., Marshall B.C., Ryan U.S., Michael J.R., Hoidal J.R. Regulation of xanthine dehydrogenase and xanthine oxidase activity and gene expression in cultured rat pulmonary endothelial cells. J. Clin. Invest. 1992, 89:197-202.
94. Pfeffer K.D., Huecksteadt T.P., Hoidal J.R. Xanthine dehydrogenase and xanthine oxidase activity and gene expression in renal epithelial cells. Cytokine and steroid regulation. J. Immunol. 1994, 153:1789-1797.
95. Sellers M.I. Further studies of interrelationship between xanthine oxidase and influenzal pneumonia in mice. Proc. Soc. Exp. Biol. Med. 1956, 91:457-460.
96. Bauer D.J., Bradley P.L. The xanthine oxidase groups; a phenomenon associated with the multiplication of neurotropic viruses. Br. J. Exp. Pathol. 1956, 37:447-460.
97. Ziegler D.W., Hutchinson H.D., Kissling R.E. Induction of xanthine oxidase by virus infections in newborn mice. Infect. Immun. 1971, 3:237-242.
98. Umezawa K., Akaike T., Fujii S., Suga M., Setoguchi K., Ozawa A., Maeda H. Induction of nitric oxide synthesis and xanthine oxidase and their roles in the antimicrobial mechanism against Salmonella typhimurium infection in mice. Infect. Immun. 1997, 65:2932-2940.
99. Falciani F., Terao M., Goldwurm S., Ronchi A., Gatti A., Minoia C., Li Calzi M., Salmona M., Cazzaniga G., Garattini E. Molybdenum(VI) salts convert the xanthine oxidoreductase apoprotein into the active enzyme in mouse L929 fibroblastic cells. Biochem. J. 1994, 298:69-77.
100. Mendel R.R., Bittner F. Cell biology of molybdenum. Biochim. Biophys. Acta 2006, 1763:621-635.
101. Della Corte E., Stirpe F. The regulation of rat liver xanthine oxidase. Involvement of thiol groups in the conversion of the enzyme activity from dehydrogenase (type D) into oxidase (type O) and purification of the enzyme. Biochem. J. 1972, 126:739-745.
102. Harris C.M., Massey V. The reaction of reduced xanthine dehydrogenase with molecular oxygen. Reaction kinetics and measurement of superoxide radical. J. Biol. Chem. 1997, 272:8370-8379.
103. Maia L., Vala A., Mira L. NADH oxidase activity of rat liver xanthine dehydrogenase and xanthine oxidase - contribution for damage mechanisms. Free Radic. Res. 2005, 39:979-986.
104. Ichida K., Matsumura T., Sakuma R., Hosoya T., Nishino T. Mutation of human molybdenum cofactor sulfurase gene is responsible for classical xanthinuria type II. Biochem. Biophys. Res. Commun. 2001, 282:1194-1200.
105. Brown A.M., Benboubetra M., Ellison M., Powell D., Reckless J.D., Harrison R. Molecular activation-deactivation of xanthine oxidase in human milk. Biochim. Biophys. Acta 1995, 1245:248-254.
106. Terada L.S., Piermattei D., Shibao G.N., McManaman J.L., Wright R.M. Hypoxia regulates xanthine dehydrogenase activity at pre- and posttranslational levels. Arch. Biochem. Biophys. 1997, 348:163-168.
107. Battelli M.G., Buonamici L., Virgili M., Abbondanza A., Contestabile A. Simulated ischaemia-reperfusion conditions increase xanthine dehydrogenase and oxidase activities in rat brain slices. Neurochem. Int. 1998, 32:17-21.
108. Hassoun P.M., Yu F.S., Cote C.G., Zulueta J.J., Sawhney R., Skinner K.A., Skinner H.B., Parks D.A., Lanzillo J.J. Upregulation of xanthine oxidase by lipopolysaccharide, interleukin-1, and hypoxia. Role in acute lung injury. Am. J. Respir. Crit. Care Med. 1998, 158:299-305.
109. Lanzillo J.J., Yu F.S., Stevens J., Hassoun P.M. Determination of xanthine dehydrogenase mRNA by a reverse transcription-coupled competitive quantitative polymerase chain reaction assay: regulation in rat endothelial cells by hypoxia and hyperoxia. Arch. Biochem. Biophys. 1996, 335:377-380.
110. Li C., Jackson R.M. Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am. J. Physiol. Cell Physiol. 2002, 282:C227-C241.
111. Wang G., Qian P., Jackson F.R., Qian G., Wu G. Sequential activation of JAKs, STATs and xanthine dehydrogenase/oxidase by hypoxia in lung microvascular endothelial cells. Int. J. Biochem. Cell Biol. 2008, 40:461-470.
112. Poss W.B., Huecksteadt T.P., Panus P.C., Freeman B.A., Hoidal J.R. Regulation of xanthine dehydrogenase and xanthine oxidase activity by hypoxia. Am. J. Physiol. 1996, 270:L941-L946.
113. Linder N., Martelin E., Lapatto R., Raivio K.O. Posttranslational inactivation of human xanthine oxidoreductase by oxygen under standard cell culture conditions. Am. J. Physiol. Cell Physiol. 2003, 285:C48-C55.
114. Stirpe F., Della Corte E. The regulation of rat liver xanthine oxidase. Conversion in vitro of the enzyme activity from dehydrogenase (type D) to oxidase (type O). J. Biol. Chem. 1969, 244:3855-3863.
115. Battelli M.G. Enzymic conversion of rat liver xanthine oxidase from dehydrogenase (D form) to oxidase (O form). FEBS Lett. 1980, 113:47-51.
116. Clare D.A., Blakistone B.A., Swaisgood H.E., Horton H.R. Sulfhydryl oxidase-catalyzed conversion of xanthine dehydrogenase to xanthine oxidase. Arch. Biochem. Biophys. 1981, 211:44-47.
117. Battelli M.G., Lorenzoni E. Purification and properties of a new glutathione-dependent thiol:disulphide oxidoreductase from rat liver. Biochem. J. 1982, 207:133-138.
118. Kamiński Z.W., Jezewska M.M. Intermediate dehydrogenase-oxidase form of xanthine oxidoreductase in rat liver. Biochem. J. 1979, 181:177-182.
119. Abbondanza A., Battelli M.G., Soffritti M., Cessi C. Xanthine oxidase status in ethanol-intoxicated rat liver. Alcohol. Clin. Exp. Res. 1989, 13:841-844.
120. Battelli M.G., Lorenzoni E., Stripe F. Milk xanthine oxidase type D (dehydrogenase) and type O (oxidase). Purification, interconversion and some properties. Biochem. J. 1973, 131:191-198.
121. Sáez J.C., Ward P.H., Günther B., Vivaldi E. Superoxide radical involvement in the pathogenesis of burn shock. Circ. Shock. 1984, 12:229-239.
122. Athar M., Elmets C.A., Bickers D.R., Mukhtar H. A novel mechanism for the generation of superoxide anions in hematoporphyrin derivative-mediated cutaneous photosensitization. Activation of the xanthine oxidase pathway. J. Clin. Invest. 1989, 83:1137-1143.
123. Sultatos L.G. Effects of acute ethanol administration on the hepatic xanthine dehydrogenase/oxidase system in the rat. J. Pharmacol. Exp. Ther. 1988, 246:946-949.
124. Battelli M.G., Abbondanza A., Stirpe F. Effects of hypoxia and ethanol on the xanthine oxidase of isolated hepatocytes: conversion from D to O form and leakage from cells. Chem. Biol. Interact. 1992, 83:73-84.
125. Cighetti G., Debiasi S., Paroni R. Effect of glutathione depletion on the conversion of xanthine dehydrogenase to oxidase in rat liver. Biochem. Pharmacol. 1993, 45:2359-2361.
126. Friedl H.P., Till G.O., Ryan U.S., Ward P.A. Mediator-induced activation of xanthine oxidase in endothelial cells. FASEB J. 1989, 3:2512-2518.
127. Phan S.H., Gannon D.E., Varani J., Ryan U.S., Ward P.A. Xanthine oxidase activity in rat pulmonary artery endothelial cells and its alteration by activated neutrophils. Am. J. Pathol. 1989, 134:1201-1211.
128. Wakabayashi Y., Fujita H., Morita I., Kawaguchi H., Murota S. Conversion of xanthine dehydrogenase to xanthine oxidase in bovine carotid artery endothelial cells induced by activated neutrophils: involvement of adhesion molecules. Biochim. Biophys. Acta 1995, 1265:103-109.
129. Atlante A., Gagliardi S., Minervini G.M., Ciotti M.T., Marra E., Calissano P. Glutamate neurotoxicity in rat cerebellar granule cells: a major role for xanthine oxidase in oxygen radical formation. J. Neurochem. 1997, 68:2038-2045.
130. Battelli M.G., Buonamici L., Polito L., Bolognesi A., Stirpe F. Hepatotoxicity of ricin, saporin or a saporin immunotoxin: xanthine oxidase activity in rat liver and blood serum. Virchows Arch. 1996, 427:529-535.
131. Gwinner W., Plasger J., Brandes R.P., Kubat B., Schulze M., Regele H., Kerjaschki D., Olbricht C.J., Koch K.M. Role of xanthine oxidase in passive Heymann nephritis in rats. J. Am. Soc. Nephrol. 1999, 10:538-544.
132. Deliconstantinos G., Villiotou V., Stavrides J.C. Alterations of nitric oxide synthase and xanthine oxidase activities of human keratinocytes by ultraviolet B radiation. Potential role for peroxynitrite in skin inflammation. Biochem. Pharmacol. 1996, 51:1727-1738.
133. Srivastava M., Kale R.K. Radiomodfication of xanthine oxidoreductase system in the liver of mice by phenylmethylsulfonyl fluoride and dithiothreitol. Radiat. Res. 2000, 154:94-103.
134. Sugawara N., Ohta T., Lai Y.R., Sugawara C., Yuasa M., Nakamura M., Tamura M. Iron depletion prevents adenine nucleotide decomposition and an increase of xanthine oxidase activity in the liver of the Long Evans Cinnamon (LEC) rat, an animal model of Wilson's disease. Life Sci. 1999, 65:1423-1431.
135. Schimpl G., Pesendorfer P., Kuesz A.M., Ratschek M., Höllwarth M.E. The impact of hepatic xanthine oxidase and xanthine dehydrogenase activities on liver function in chronic cholestasis. Pediatr. Surg. Int. 2000, 16:297-301.
136. Ramachandran A., Prabhu R., Thomas S., Reddy J.B., Pulimood A., Balasubramanian K.A. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology 2002, 35:622-629.
137. Kaminsky Y., Kosenko E. AMP deaminase and adenosine deaminase activities in liver and brain regions in acute ammonia intoxication and subacute toxic hepatitis. Brain Res. 2010, 1311:175-181.
138. Engerson T.D., McKelvey T.G., Rhyne D.B., Boggio E.B., Snyder S.J., Jones H.P. Conversion of xanthine dehydrogenase to oxidase in ischemic rat tissues. J. Clin. Invest. 1987, 79:1564-1570.
139. McKelvey T.G., Höllwarth M.E., Granger D.N., Engerson T.D., Landler U., Jones H.P. Mechanisms of conversion of xanthine dehydrogenase to xanthine oxidase in ischemic rat liver and kidney. Am. J. Physiol. 1988, 254:G753-G760.
140. Parks D.A., Williams T.K., Beckman J.S. Conversion of xanthine dehydrogenase to oxidase in ischemic rat intestine: a reevaluation. Am. J. Physiol. 1988, 254:G768-G774.
141. Brass C.A., Narciso J., Gollan J.L. Enhanced activity of the free radical producing enzyme xanthine oxidase in hypoxic rat liver. Regulation and pathophysiologic significance. J. Clin. Invest. 1991, 87:424-431.
142. Kinuta Y., Kikuchi H., Ishikawa M. Ischaemic brain oedema and xanthine-xanthine oxidase system. Acta Neurochir. Suppl. (Wien) 1990, 51:192-194.
143. Oka H., Kanemitsu H., Nihei H., Nakayama H., Tamura A., Sano K. Change of xanthine dehydrogenase and xanthine oxidase activities in rat brain following complete ischaemia. Neurol. Res. 1992, 14:321-324.
144. Thom S.R. Dehydrogenase conversion to oxidase and lipid peroxidation in brain after carbon monoxide poisoning. J. Appl. Physiol. 1992, 73:1584-1589.
145. de Groot H., Littauer A. Reoxygenation injury in isolated hepatocytes: cell death precedes conversion of xanthine dehydrogenase to xanthine oxidase. Biochem. Biophys. Res. Commun. 1988, 155:278-282.
146. McCord J.M. Oxygen-derived free radicals in postischemic tissue injury. N. Engl. J. Med. 1985, 312:159-163.
147. Bulkley G.B. Free radical-mediated reperfusion injury: a selective review. Br. J. Cancer Suppl. 1987, 8:66-73.
148. Granger D.N. Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am. J. Physiol. 1988, 255:H1269-H1275.
149. Fellman V., Raivio K.O. Reperfusion injury as the mechanism of brain damage after perinatal asphyxia. Pediatr. Res. 1997, 41:599-606.
150. Pacher P., Nivorozhkin A., Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev. 2006, 58:87-114.
151. Cappola T.P., Kass D.A., Nelson G.S., Berger R.D., Rosas G.O., Kobeissi Z.A., Marbán E., Hare J.M. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001, 104:2407-2411.
152. Sola A., Hotter G., Prats N., Xaus C., Gelpi E., Roselló-Catafau J. Modification of oxidative stress in response to intestinal preconditioning. Transplantation 2000, 69:767-772.
153. Jaeschke H. Xanthine oxidase-induced oxidant stress during hepatic ischemia-reperfusion: are we coming full circle after 20years?. Hepatology 2002, 36:761-763.
154. de Groot H., Littauer A. Hypoxia, reactive oxygen, and cell injury. Free Radic. Biol. Med. 1989, 6:541-551.
155. Ledingham S.J., Katayama O., Lachno D.R., Yacoub M. Prolonged cardiac preservation. Evaluation of the University of Wisconsin preservation solution by comparison with the St. Thomas' Hospital cardioplegic solutions in the rat. Circulation 1990, 82:IV351-IV358.
156. Sun K., Kiss E., Bedke J., Stojanovic T., Li Y., Gwinner W., Gröne H.J. Role of xanthine oxidoreductase in experimental acute renal-allograft rejection. Transplantation 2004, 77:1683-1692.
157. Peralta C., Bulbena O., Xaus C., Prats N., Cutrin J.C., Poli G., Gelpi E., Roselló-Catafau J. Ischemic preconditioning: a defense mechanism against the reactive oxygen species generated after hepatic ischemia reperfusion. Transplantation 2002, 73:1203-1211.
158. Fernández L., Heredia N., Grande L., Gómez G., Rimola A., Marco A., Gelpí E., Roselló-Catafau J., Peralta C. Preconditioning protects liver and lung damage in rat liver transplantation: role of xanthine/xanthine oxidase. Hepatology 2002, 36:562-572.
159. Fernández L., Carrasco-Chaumel E., Serafín A., Xaus C., Grande L., Rimola A., Roselló-Catafau J., Peralta C. Is ischemic preconditioning a useful strategy in steatotic liver transplantation?. Am. J. Transplant. 2004, 4:888-899.
160. Rootwelt T., Almaas R., Øyasæter S., Moen A., Saugstad O.D. Release of xanthine oxidase to the systemic circulation during resuscitation from severe hypoxemia in newborn pigs. Acta Paediatr. 1995, 84:507-511.
161. Al-Khalidi U.A.S., Geha R.S. The sensitivity of serum xanthine oxidase and serum glutamic pyruvic transaminase in detecting liver damage. Clin. Chim. Acta 1966, 14:833-835.
162. Affonso O.R., Mitidieri E., Ribeiro L.P., Villela G.G. Blood serum xanthine oxidase of rats poisoned with carbon tetrachloride. Proc. Soc. Exp. Biol. Med. 1955, 90:527-529.
163. Ramboer C., Piessens F., de Groote J. Serum xanthine oxidase and liver disease. Digestion 1972, 7:183-195.
164. Affonso O.R., Mitidieri E., Villela G.G. Effect of colchicine on rat blood serum xanthine oxidase. Nature 1962, 193:64.
165. Giler S., Ventura E., Levy E., Urca I., Sperling O., de Vries A. Elevation of serum xanthine oxidase following halothane anesthesia in the rat. Experientia 1976, 32:620-621.
166. Zima T., Novák L., Stípek S. Plasma xanthine oxidase level and alcohol administration. Alcohol Alcohol. 1993, 28:693-694.
167. Moumen R., Ait-Oukhatar N., Bureau F., Fleury C., Bouglé D., Arhan P., Neuville D., Viader F. Aluminium increases xanthine oxidase activity and disturbs antioxidant status in the rat. J. Trace Elem. Med. Biol. 2001, 15:89-93.
168. Till G.O., Friedl H.P., Ward P.A. Lung injury and complement activation: role of neutrophils and xanthine oxidase. Free Radic. Biol. Med. 1991, 10:379-386.
169. Yagci R., Aydin B., Erdurmus M., Karadag R., Gurel A., Durmus M., Yigitoglu R. Use of melatonin to prevent selenite-induced cataract formation in rat eyes. Curr. Eye Res. 2006, 31:845-850.
170. Oda T., Akaike T., Hamamoto T., Suzuki F., Hirano T., Maeda H. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science 1989, 244:974-976.
171. Akaike T., Ando M., Oda T., Doi T., Ijiri S., Araki S., Maeda H. Dependence on O2-generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. J. Clin. Invest. 1990, 85:739-745.
172. Ungheri D., Pisani C., Sanson G., Bertani A., Schioppacassi G., Delgado R., Sironi M., Ghezzi P. Protective effect of n-acetylcysteine in a model of influenza infection in mice. Int. J. Immunopathol. Pharmacol. 2000, 13:123-128.
173. Friedl H.P., Till G.O., Trentz O., Ward P.A. Roles of histamine, complement and xanthine oxidase in thermal injury of skin. Am. J. Pathol. 1989, 135:203-217.
174. Burton L.K., Velasco S.E., Patt A., Terada L.S., Repine J.E. Xanthine oxidase contributes to lung leak in rats subjected to skin burn. Inflammation 1995, 19:31-38.
175. Koizumi T., Tanaka H., Sakaki S., Shimazaki S. The therapeutic efficacy of edaravone in extensively burned rats. Arch. Surg. 2006, 141:992-995.
176. Kahl S., Elsasser T.H. Endotoxin challenge increases xanthine oxidase activity in cattle: effect of growth hormone and vitamin E treatment. Domest. Anim. Endocrinol. 2004, 26:315-328.
177. White C.R., Darley-Usmar V., Berrington W.R., McAdams M., Gore J.Z., Thompson J.A., Parks D.A., Tarpey M.M., Freeman B.A. Circulating plasma xanthine oxidase contributes to vascular disfunction in hypercholesterolemic rabbits. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:8745-8749.
178. Desco M.C., Asensi M., Márquez R., Martínez-Valls J., Vento M., Pallardó F.V., Sastre J., Viña J. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002, 51:1118-1124.
179. Matsumoto S., Koshiishi I., Inoguchi T., Nawata H., Utsumi H. Confirmation of superoxide generation via xanthine oxidase in streptozotocin-induced diabetic mice. Free Radic. Res. 2003, 37:767-772.
180. Chen L., Lan Z., Lin Q., Mi X., He Y., Wei L., Lin Y., Zhang Y., Deng X. Polydatin ameliorates renal injury by attenuating oxidative stress-related inflammatory responses in fructose-induced urate nephropathic mice. Food Chem. Toxicol. 2013, 52:28-35.
181. Dagher F.J., Panossian A., Saab S. The effect of experimental ligation of the superior mesenteric artery on serum xanthine oxidase and transaminase activity. Surgery 1967, 62:1044-1050.
182. Nielsen V.G., Weinbroum A., Tan S., Samuelson P.N., Gelman S., Parks D.A. Xanthine oxidoreductase release after descending thoracic aorta occlusion and reperfusion in rabbits. J. Thorac. Cardiovasc. Surg. 1994, 107:1222-1227.
183. Nielsen V.G., McCammon A.T., Tan S., Kirk K.A., Samuelson P.N., Parks D.A. Xanthine oxidase inactivation attenuates postocclusion shock after descending thoracic aorta occlusion and reperfusion in rabbits. J. Thorac. Cardiovasc. Surg. 1995, 110:715-722.
184. Nielsen V.G., Tan S., Weinbroum A., McCammon A.T., Samuelson P.N., Gelman S., Parks D.A. Lung injury after hepatoenteric ischemia-reperfusion: role of xanthine oxidase. Am. J. Respir. Crit. Care Med. 1996, 154:1364-1369.
185. Nielsen V.G., Tan S., Baird M.S., McCammon A.T., Parks D.A. Gastric intramucosal pH and multiple organ injury: impact of ischemia-reperfusion and xanthine oxidase. Crit. Care Med. 1996, 24:1339-1344.
186. Nielsen V.G., Tan S., Baird M.S., Samuelson P.N., McCammon A.T., Parks D.A. Xanthine oxidase mediates myocardial injury after hepatoenteric ischemia-reperfusion. Crit. Care Med. 1997, 25:1044-1050.
187. Terada L.S., Dormish J.J., Shanley P.F., Leff J.A., Anderson B.O., Repine J.E. Circulating xanthine oxidase mediates lung neutrophil sequestration after intestinal ischemia-reperfusion. Am. J. Physiol. 1992, 263:L394-L401.
188. Vega V.L., Mardones L., Maldonado M., Nicovani S., Manríquez V., Roa J., Ward P.H. Xanthine oxidase released from reperfused hind limbs mediate kupffer cell activation, neutrophil sequestration, and hepatic oxidative stress in rats subjected to tourniquet shock. Shock 2000, 14:565-571.
189. Tan S., Yokoyama Y., Dickens E., Cash T.G., Freeman B.A., Parks D.A. Xanthine oxidase activity in the circulation of rats following hemorrhagic shock. Free Radic. Biol. Med. 1993, 15:407-414.
190. Mayumi T., Chan C.K., Clemens M.G., Bulkley G.B. Zonal heterogeneity of hepatic injury following shock/resuscitation: relationship of xanthine oxidase activity to localization of neutrophil accumulation and central lobular necrosis. Shock 1996, 5:324-332.
191. Tan S., Yokoyama Y., Wang Z., Zhou F., Nielsen V., Murdoch A.D., Adams C., Parks D.A. Hypoxia-reoxygenation is as damaging as ischemia-reperfusion in the rat liver. Crit. Care Med. 1998, 26:1089-1095.
192. Yokoyama Y., Beckman J.S., Beckman T.K., Wheat J.K., Cash T.G., Freeman B.A., Parks D.A. Circulating xanthine oxidase: potential mediator of ischemic injury. Am. J. Physiol. 1990, 258:G564-G570.
193. Weinbroum A., Nielsen V.G., Tan S., Gelman S., Matalon S., Skinner K.A., Bradley E., Parks D.A. Liver ischemia-reperfusion increases pulmonary permeability in rat: Role of circulating xanthine oxidase. Am. J. Physiol. 1995, 31:G988-G996.
194. Khoury W., Namnesnikov M., Fedorov D., Abu-Gazala S., Weinbroum A.A. Mannitol attenuates kidney damage induced by xanthine oxidase-associated pancreas ischemia-reperfusion. J. Surg. Res. 2010, 160:163-168.
195. Sisley A.C., Desai T., Harig J.M., Gewertz B.L. Neutrophil depletion attenuates human intestinal reperfusion injury. J. Surg. Res. 1994, 57:192-196.
196. Tian X.X., Wang B.L., Cao Y.Z., Zhong Y.X., Tu Y.Y., Xiao J.B., He Q.F., Zhai L.N. Comparison of protective effects of Safflor Injection and extract of Ginkgo biloba on lung ischemia/reperfusion injury in rabbits. Chin. J. Integr. Med. Oct 19 2013, (Epub ahead of print). 10.1007/s11655-013-1513-8.
197. Wilkins E.G., Rees R.S., Smith D., Cashmer B., Punch J., Till G.O., Smith D.J. Identification of xanthine oxidase activity following reperfusion in human tissue. Ann. Plast. Surg. 1993, 31:60-65.
198. Newaz M.A., Adeeb N.N. Detection of xanthine oxidase in human plasma. Med. J. Malaysia 1998, 53:70-75.
199. Shamma'a M.H., Nasrallah S., Chaglassian T., Kachadurian A.K., Al-Khalidi U.A.S. Serum xanthine oxidase: a sensitive test of acute liver injury. Gastroenterology 1965, 48:226-230.
200. Shamma'a M.H., Nasrallah S.M., AI-Khalidi U.A.S. Serum xanthine oxidase. An experience with 2000 patients. Am. J. Dig. Dis. 1973, 18:15-22.
201. Wolko K., Krawczynski J. Diagnostic value of determination of serum xanthine oxidase activity in acute viral hepatitis. Mater. Med. Pol. 1974, 6:95-98.
202. Giler S., Sperling O., Brosh S., Urca I., de Vries A. Serum xanthine oxidase in jaundice. Clin. Chim. Acta 1975, 63:37-40.
203. Battelli M.G., Musiani S., Valgimigli M., Gramantieri L., Tomassoni F., Bolondi L., Stirpe F. Serum xanthine oxidase in human liver disease. Am. J. Gastroenterol. 2001, 96:1194-1199.
204. Miesel R., Zuber M. Elevated levels of xanthine oxidase in serum of patients with inflammatory and autoimmune rheumatic diseases. Inflammation 1993, 17:551-561.
205. Akyol O., Gokbulut I., Koksal N., Akin H., Ozyurt H., Yildirim Z. The activities of purine catabolizing enzymes in plasma and bronchial washing fluid in patients with lung cancer and pneumonia. Clin. Biochem. 2001, 34:251-254.
206. Mete R., Tulubas F., Oran M., Yilmaz A., Avci B.A., Yildiz K., Turan C.B., Gurel A. The role of oxidants and reactive nitrogen species in irritable bowel syndrome: a potential etiological explanation. Med. Sci. Monit. 2013, 19:762-766.
207. Akyol O., Herken H., Uz E., Fadillioǧlu E., Unal S., Söǧüt S., Ozyurt H., Savaş H.A. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:995-1005.
208. Cosić V., Antić S., Pesić M., Jovanović O., Kundalić S., Djordjević V.B. Monotherapy with metformin: does it improve hypoxia in type 2 diabetic patients?. Clin. Chem. Lab. Med. 2001, 39:818-821.
209. Kuppusamy U.R., Indran M., Rokiah P. Glycaemic control in relation to xanthine oxidase and antioxidant indices in Malaysian Type 2 diabetes patients. Diabet. Med. 2005, 22:1343-1346.
210. Miric D.J., Kisic B.B., Zoric L.D., Mitic R.V., Miric B.M., Dragojevic I.M. Xanthine oxidase and lens oxidative stress markers in diabetic and senile cataract patients. J. Diabetes Complicat. 2013, 27:171-176.
211. Giler S., Eshel Y., Pinkhas J., Ventura E., Levy E., Urca I., Sperling O., de Vries A. Elevation of serum xanthine oxidase following halothane anesthesia in man. Experientia 1977, 33:1356-1358.
212. Grattagliano I., Vendemiale G., Sabba C., Buonamico P., Altomare E. Oxidation of circulating proteins in alcoholics: role of acetaldehyde and xanthine oxidase. J. Hepatol. 1996, 25:28-36.
213. Dagher F.J., Saab S., Panossian A. Postoperative determinations of serum xanthine oxidase, and serum glutamic and oxalacetic and pyruvic transaminase. Surg. Gynecol. Obstet. 1969, 128:985-990.
214. Giler S., Sperling O., Brosh S., Urca I., de Vries A. Elevated serum xanthine oxidase activity following biliary tract and gastric surgery. Int. Surg. 1976, 61:153-155.
215. Iwalokun B.A., Bamiro S.B., Ogunledun A. Levels and interactions of plasma xanthine oxidase, catalase and liver function parameters in Nigerian children with Plasmodium falciparum infection. APMIS 2006, 114:842-850.
216. Aslan M., Ryan T.M., Adler B., Townes T.M., Parks D.A., Thompson J.A., Tousson A., Gladwin M.T., Patel R.P., Tarpey M.M., Batinic-Haberle I., White C.R., Freeman B.A. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:15215-15220.
217. Grum C.M., Ragsdale R.A., Ketai L.H., Simon R.H. Plasma xanthine oxidase activity in patients with adult respiratory distress syndrome. J. Crit. Care 1987, 2:22-26.
218. Supnet M.C., David-Cu R., Walther F.J. Plasma xanthine oxidase activity and lipid hydroperoxide levels in preterm infants. Pediatr. Res. 1994, 36:283-287.
219. Mitropoulos D., Deliconstantinos G., Zervas A., Villiotou V., Dimopoulos C., Stavrides J. Nitric oxide synthase and xanthine oxidase activities in the spermatic vein of patients with varicocele: a potential role for nitric oxide and peroxynitrite in sperm dysfunction. J. Urol. 1996, 156:1952-1958.
220. Friedl H.P., Smith D.J., Till G.O., Thomson P.D., Louis D.S., Ward P.A. Ischemia-reperfusion in humans - appearance of xanthine oxidase activity. Am. J. Pathol. 1990, 136:491-495.
221. Friedl H.P., Till G.O., Trentz O., Ward P.A. Role of oxygen radicals in tourniquet-related ischemia-reperfusion injury of human patients. Klin. Wochenschr. 1991, 69:1109-1112.
222. Mathru M., Dries D.J., Barnes L., Tonino P., Sukhani R., Rooney M.W. Tourniquet-induced exsanguination in patients requiring lower limb surgery. An ischemia-reperfusion model of oxidant and antioxidant metabolism. Anesthesiology 1996, 84:14-22.
223. Tan S., Gelman S., Wheat J.K., Parks D.A. Circulating xanthine oxidase in human ischemia reperfusion. South. Med. J. 1995, 88:479-482.
224. Karabulut A.B., Kafkasli A., Burak F., Gozukara E.M. Maternal and fetal plasma adenosine deaminase, xanthine oxidase and malondialdehyde levels in pre-eclampsia. Cell Biochem. Funct. 2005, 23:279-283.
225. Yildirim A., Altinkaynak K., Aksoy H., Sahin Y.N., Akcay F. Plasma xanthine oxidase, superoxide dismutase and glutathione peroxidase activities and uric acid levels in severe and mild pre-eclampsia. Cell Biochem. Funct. 2004, 22:213-217.
226. Pesonen E.J., Linder N., Raivio K.O., Sarnesto A., Lapatto R., Hockerstedt K., Makisalo H., Andersson S. Circulating xanthine oxidase and neutrophil activation during human liver transplantation. Gastroenterology 1998, 114:1009-1015.
227. Martí R., Múrio E., Varela E., Bilbao I., Pascual C., Margarit C., Segura R.M. Xanthine oxidoreductase and preservation injury in human liver transplantation. Transplantation 2004, 77:1239-1245.
228. Battelli M.G., Ravaioli M., Musiani S., Scicchitano V., Grazi G.L., Bolognesi A. Increased serum level of xanthine oxidoreductase in liver transplanted patients. J. Biol. Regul. Homeost. Agents 2011, 25:77-84.
229. Dołegowska B., Błogowski W., Domański L. Clinical evidence of the association between serum perioperative changes in xanthine metabolizing enzymes activity and early post-transplant kidney allograft function. J. Am. Coll. Surg. 2010, 211:587-595.
230. Kwiatkowska E., Kedzierska K., Bober J., Dołegowska B., Dziedziejko V., Gołembiewska E., Ciechanowski K., Wiśniewska M. Urinary hepatocyte growth factor indicates ischemia/reperfusion injury after kidney transplantation. Pol. Arch. Med. Wewn. 2010, 120:437-442.
231. Jarasch E.D., Bruder G., Heid H.W. Significance of xanthine oxidase in capillary endothelial cells. Acta Physiol. Scand. Suppl. 1986, 548:39-46.
232. Kooij A., Schiller H.J., Schijns M., Van Noorden C.J.F., Frederiks W.M. Conversion of xanthine dehydrogenase into xanthine oxidase in rat liver and plasma at the onset of reperfusion after ischemia. Hepatology 1994, 19:1488-1495.
233. Adachi T., Fukushima T., Usami Y., Hirano K. Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial-cell surface. Biochem. J. 1993, 289:523-527.
234. Houston M., Estevez A., Chumley P., Aslan M., Marklund S., Parks D.A., Freeman B.A. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J. Biol. Chem. 1999, 274:4985-4994.
235. Poggetti R.S., Moore F.A., Moore E.E., Koeike K., Banerjee A. Simultaneous liver and lung injury following gut ischemia is mediated by xanthine oxidase. J. Trauma 1992, 32:723-727.
236. Koike K., Moore F.A., Moore E.E., Read R.A., Carl V.S., Banerjee A. Gut ischemia mediates lung injury by a xanthine oxidase-dependent neutrophil mechanism. J. Surg. Res. 1993, 54:469-473.
237. Axon R.N., Baird M.S., Lang J.D., Brix A.E., Nielsen V.G. PentaLyte decreases lung injury after aortic occlusion-reperfusion. Am. J. Respir. Crit. Care Med. 1998, 157:1982-1990.
238. Carden D.L., Granger D.N. Pathophysiology of ischaemia-reperfusion injury. J. Pathol. 2000, 190:255-266.
239. Shafik A.N. Febuxostat improves the local and remote organ changes induced by intestinal ischemia/reperfusion in rats. Dig. Dis. Sci. 2013, 58:650-659.
240. Allan G., Cambridge D., Lee-Tsang-Tan L., Van Way C.W., Whiting M.V. The protective action of allopurinol in an experimental model of haemorrhagic shock and reperfusion. Br. J. Pharmacol. 1986, 89:149-155.
241. Chan P.H., Schmidley J.W., Fishman R.A., Longar S.M. Brain injury, edema, and vascular permeability changes induced by oxygen-derived free radicals. Neurology 1984, 34:315-320.
242. Tapuria N., Kumar Y., Habib M.M., Abu Amara M., Seifalian A.M., Davidson B.R. Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury-a review. J. Surg. Res. 2008, 150:304-330.
243. Santos C.X., Anilkumar N., Zhang M., Brewer A.C., Shah A.M. Redox signaling in cardiac myocytes. Free Radic. Biol. Med. 2011, 50:777-793.
244. Granger D.N. Ischemia-reperfusion: mechanisms of microvascular dysfunction and the influence of risk factors for cardiovascular disease. Microcirculation 1999, 6:167-178.
245. Seal J.B., Gewertz B.L. Vascular dysfunction in ischemia-reperfusion injury. Ann. Vasc. Surg. 2005, 19:572-584.
246. Meneshian A., Bulkley G.B. The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation 2002, 9:161-175.
247. Wright R.M., Ginger L.A., Kosila N., Elkins N.D., Essary B., McManaman J.L., Repine J.E. Mononuclear phagocyte xanthine oxidoreductase contributes to cytokine-induced acute lung injury. Am. J. Respir. Cell Mol. Biol. 2004, 30:479-490.
248. Gibbings S., Elkins N.D., Fitzgerald H., Tiao J., Weyman M.E., Shibao G., Fini M.A., Wright R.M. Xanthine oxidoreductase promotes the inflammatory state of mononuclear phagocytes through effects on chemokine expression, peroxisome proliferator-activated receptor-{gamma} sumoylation, and HIF-1{alpha}. J. Biol. Chem. 2011, 286:961-975.
249. Nicholas S.A., Bubnov V.V., Yasinska I.M., Sumbayev V.V. Involvement of xanthine oxidase and hypoxia-inducible factor 1 in Toll-like receptor 7/8-mediated activation of caspase 1 and interleukin-1beta. Cell. Mol. Life Sci. 2011, 68:151-158.
250. de Jong J.W., Schoemaker R.G., de Jonge R., Bernocchi P., Keijzer E., Harrison R., Sharma H.S., Ceconi C. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J. Mol. Cell. Cardiol. 2000, 32:2083-2089.
251. Ekelund U.E., Harrison R.W., Shokek O., Thakkar R.N., Tunin R.S., Senzaki H., Kass D.A., Marbán E., Hare J.M. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ. Res. 1999, 85:437-445.
252. Saavedra W.F., Paolocci N., St John M.E., Skaf M.W., Stewart G.C., Xie J.S., Harrison R.W., Zeichner J., Mudrick D., Marbán E., Kass D.A., Hare J.M. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ. Res. 2002, 90:297-304.
253. Amado L.C., Saliaris A.P., Raju S.V., Lehrke S., St John M., Xie J., Stewart G., Fitton T., Minhas K.M., Brawn J., Hare J.M. Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. J. Mol. Cell. Cardiol. 2005, 39:531-536.
254. Mellin V., Isabelle M., Oudot A., Vergely-Vandriesse C., Monteil C., Di Meglio B., Henry J.P., Dautreaux B., Rochette L., Thuillez C., Mulder P. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur. Heart J. 2005, 26:1544-1550.
255. Kögler H., Fraser H., McCune S., Altschuld R., Marbán E. Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc. Res. 2003, 59:582-592.
256. Naumova A.V., Chacko V.P., Ouwerkerk R., Stull L., Marbán E., Weiss R.G. Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H837-H843.
257. Ali O.S., Abdelgawad H.M., Mohammed M.S., El-Awady R.R. Ischemic heart diseases in Egypt: role of xanthine oxidase system and ischemia-modified albumin. Heart Vessels Oct 4 2013, (Epub ahead of print). 10.1007/s00380-013-0413-3.
258. Doehner W., Schoene N., Rauchhaus M., Leyva-Leon F., Pavitt D.V., Reaveley D.A., Schuler G., Coats A.J., Anker S.D., Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002, 105:2619-2624.
259. Farquharson C.A., Butler R., Hill A., Belch J.J., Struthers A.D. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002, 106:221-226.
260. Baldus S., Köster R., Chumley P., Heitzer T., Rudolph V., Ostad M.A., Warnholtz A., Staude H.J., Thuneke F., Koss K., Berger J., Meinertz T., Freeman B.A., Münzel T. Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic. Biol. Med. 2005, 39:1184-1190.
261. Cingolani H.E., Plastino J.A., Escudero E.M., Mangal B., Brown J., Pérez N.G. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J. Card. Fail. 2006, 12:491-498.
262. Khan F., George J., Wong K., McSwiggan S., Struthers A.D., Belch J.J. Allopurinol treatment reduces arterial wave reflection in stroke survivors. Cardiovasc. Ther. 2008, 26:247-252.
263. Muir S.W., Harrow C., Dawson J., Lees K.R., Weir C.J., Sattar N., Walters M.R. Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial. Stroke 2008, 39:3303-3307.
264. Hare J.M., Mangal B., Brown J., Fisher C., Freudenberger R., Colucci W.S., Mann D.L., Liu P., Givertz M.M., Schwarz R.P., OPT-CHF Investigators Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J. Am. Coll. Cardiol. 2008, 51:2301-2309.
265. Landmesser U., Spiekermann S., Preuss C., Sorrentino S., Fischer D., Manes C., Mueller M., Drexler H. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler. Thromb. Vasc. Biol. 2007, 27:943-948.
266. Gonzalez D.R., Treuer A.V., Castellanos J., Dulce R.A., Hare J.M. Impaired S-nitrosylation of the ryanodine receptor caused by xanthine oxidase activity contributes to calcium leak in heart failure. J. Biol. Chem. 2010, 285:28938-28945.
267. Sawyer D.B., Siwik D.A., Xiao L., Pimentel D.R., Singh K., Colucci W.S. Role of oxidative stress in myocardial hypertrophy and failure. J. Mol. Cell. Cardiol. 2002, 34:379-388.
268. Pinelli M., Bindi M., Moroni F., Castiglioni M. Relationship between serum uric acid levels and urinary albumin excretion in patients with heart failure. Acta Cardiol. 2008, 63:191-195.
269. Sautin Y.Y., Johnson R.J. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008, 27:608-619.
270. Viazzi F., Leoncini G., Ratto E., Pontremoli R. Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revived. J. Clin. Hypertens. (Greenwich) 2006, 8:510-518.
271. Strazzullo P., Puig J.G. Uric acid and oxidative stress: relative impact on cardiovascular risk?. Nutr. Metab. Cardiovasc. Dis. 2007, 17:409-414.
272. Suzuki I., Yamauchi T., Onuma M., Nozaki S. Allopurinol, an inhibitor of uric acid synthesis-can it be used for the treatment of metabolic syndrome and related disorders?. Drugs Today (Barc.) 2009, 45:363-378.
273. Hare J.M., Johnson R.J. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 2003, 107:1951-1952.
274. Neogi T., George J., Rekhraj S., Struthers A.D., Choi H., Terkeltaub R.A. Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum. 2012, 64:327-338.
275. Cicero A.F., Rosticci M., Parini A., Baronio C., D'Addato S., Borghi C. Serum uric acid is inversely proportional to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: data from the Brisighella Heart Study. Intern. Emerg. Med. Nov 9 2013, (Epub ahead of print). 10.1007/s11739-013-1016-9.
276. Ioachimescu A.G., Brennan D.M., Hoar B.M., Hazen S.L., Hoogwerf B.J. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum. 2008, 58:623-630.
277. Dawson J., Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?. Br. J. Clin. Pharmacol. 2006, 62:633-644.
278. Harzand A., Tamariz L., Hare J.M. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Congest. Heart Fail. 2012, 18:179-182.
279. Feig D.I., Kang D.H., Johnson R.J. Uric acid and cardiovascular risk. N. Engl. J. Med. 2008, 359:1811-1821.
280. Mazzali M., Kanbay M., Segal M.S., Shafiu M., Jalal D., Feig D.I., Johnson R.J. Uric acid and hypertension: cause or effect?. Curr. Rheumatol. Rep. 2010, 12:108-117.
281. Mazzali M., Hughes J., Kim Y.G., Jefferson J.A., Kang D.H., Gordon K.L., Lan H.Y., Kivlighn S., Johnson R.J. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001, 38:1101-1106.
282. Sánchez-Lozada L.G., Tapia E., Soto V., Avila-Casado C., Franco M., Zhao L., Johnson R.J. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol. Dial. Transplant. 2008, 23:1179-1185.
283. Stirpe F., Della Corte E., Bonetti E., Abbondanza A., Abbati A., De Stefano F. Fructose-induced hyperuricaemia. Lancet 1970, 2:1310-1311.
284. Nakagawa T., Hu H., Zharikov S., Tuttle K.R., Short R.A., Glushakova O., Ouyang X., Feig D.I., Block E.R., Herrera-Acosta J., Patel J.M., Johnson R.J. A causal role for uric acid in fructose-induced metabolic syndrome. Am. J. Physiol. Renal. Physiol. 2006, 290:F625-F631.
285. Johnson R.J., Segal M.S., Sautin Y., Nakagawa T., Feig D.I., Kang D.H., Gersch M.S., Benner S., Sánchez-Lozada L.G. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am. J. Clin. Nutr. 2007, 86:899-906.
286. Nakazono K., Watanabe N., Matsuno K., Sasaki J., Sato T., Inoue M. Does superoxide underlie the pathogenesis of hypertension?. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:10045-10048.
287. Newaz M.A., Adeeb N.N., Muslim N., Razak T.A., Htut N.N. Uric acid, xanthine oxidase and other risk factors of hypertension in normotensive subjects. Clin. Exp. Hypertens. 1996, 18:1035-1050.
288. Feig D.I., Soletsky B., Johnson R.J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008, 300:924-932.
289. George J., Struthers A.D. The role of urate and xanthine oxidase inhibitors in cardiovascular disease. Cardiovasc. Ther. 2008, 26:59-64.
290. Weseler A.R., Bast A. Oxidative stress and vascular function: implications for pharmacologic treatments. Curr. Hypertens. Rep. 2010, 12:154-161.
291. Newaz M.A., Yousefipour Z., Oyekan A. Oxidative stress-associated vascular aging is xanthine oxidase-dependent but not NAD(P)H oxidase-dependent. J. Cardiovasc. Pharmacol. 2006, 48:88-94.
292. Boueiz A., Damarla M., Hassoun P.M. Xanthine oxidoreductase in respiratory and cardiovascular disorders. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 294:L830-L840.
293. Martinez-Hervas S., Real J.T., Ivorra C., Priego A., Chaves F.J., Pallardo F.V., Viña J.R., Redon J., Carmena R., Ascaso J.F. Increased plasma xanthine oxidase activity is related to nuclear factor kappa beta activation and inflammatory markers in familial combined hyperlipidemia. Nutr. Metab. Cardiovasc. Dis. 2010, 20:734-739.
294. Yiginer O., Ozcelik F., Inanc T., Aparci M., Ozmen N., Cingozbay B.Y., Kardesoglu E., Suleymanoglu S., Sener G., Cebeci B.S. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin. Res. Cardiol. 2008, 97:334-340.
295. Higgins P., Dawson J., Lees K.R., McArthur K., Quinn T.J., Walters M.R. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc. Ther. 2012, 30:217-226.
296. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 2000, 87:840-844.
297. Sabán-Ruiz J., Alonso-Pacho A., Fabregate-Fuente M., de la Puerta González-Quevedo C. Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation. Antiinflamm. Antiallergy Agents Med. Chem. 2013, 12:94-99.
298. Xu X., Hu X., Lu Z., Zhang P., Zhao L., Wessale J.L., Bache R.J., Chen Y. Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J. Card. Fail. 2008, 14:746-753.
299. Zhao L., Roche B.M., Wessale J.L., Kijtawornrat A., Lolly J.L., Shemanski D., Hamlin R.L. Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment. Life Sci. 2008, 82:495-502.
300. Feig D.I. Serum uric acid and the risk of hypertension and chronic kidney disease. Curr. Opin. Rheumatol. 2014, 26:176-185.
301. Baker J.E., Su J., Fu X., Hsu A., Gross G.J., Tweddell J.S., Hogg N. Nitrite confers protection against myocardial infarction: role of xanthine oxidoreductase, NADPH oxidase and K(ATP) channels. J. Mol. Cell. Cardiol. 2007, 43:437-444.
302. Ghosh S.M., Kapil V., Fuentes-Calvo I., Bubb K.J., Pearl V., Milsom A.B., Khambata R., Maleki-Toyserkani S., Yousuf M., Benjamin N., Webb A.J., Caulfield M.J., Hobbs A.J., Ahluwalia A. Enhanced vasodilator activity of nitrite in hypertension: critical role for erythrocytic xanthine oxidoreductase and translational potential. Hypertension 2013, 61:1091-1102.